Robotics exec talks plans for new Houston office and the future of automation

robot revolution

Marie Myers is the CFO of UiPath and is based in the company's new Houston office. Courtesy of UiPath

It's safe to say that Marie Myers — CFO of UiPath, which opened its 71-person office in Houston earlier this year — loves her job.

The robotics process automation company, which was founded in Romania before moving its headquarters to New York City last year, is in major growth mode. At the helm of the financial side of things is Myers, who has over 20 years of experience in technology.

When Myers was working on a spinoff project for HP, she started seeing the difference software automation makes on a company's bottom line.

"I realized RPA was the fastest way to drive efficiencies, so I started building bots," she tells InnovationMap. "During that time, I came across UiPath and I saw how impressive their technology was. In my more than two-decade career, I hadn't really come across a technology that I felt that had such an impressive impact in such a short time."

She drank the UiPath Kool-Aid, and when the company came to her adopted hometown of Houston to open an office to be its central, Midwestern location, she leapt at the opportunity to join the team. Now, with several months under her belt in the position and a growing office, Myers speaks with InnovationMap about the company's growth and the revolution that RPA is having in business.

InnovationMap: You've been in your role since January, but you've been in tech for a while now. How has the transition been for you?

Marie Myers: This has been one of the most exciting times for my career. I've been in tech for about two decades. I started with Compaq — quite an incredible company that started right here in Texas. It was a very famous startup in its own time, and I had a chance to be a part of that wave, which was really incredible. Then, it got bought out by HP, and then I pivoted and spent a lot of time in Silicon Valley for a couple decades.

I got involved in robotics process automation quite by happenstance about four years ago when HP decided to split. I was involved in setting up a company from the finance and legal perspective. I got challenged to drive some cost efficiency, so I turned to RPA as a means to drive some of that impact within my own organization of a couple thousand folks.

When the opportunity came up to be CFO for UiPath, I really jumped at it because it filled two important things for me. I wanted to be a leader of a finance organization and team. Secondly, I wanted to do something where I was really passionate about the technology. When I think about RPA, the world lights up for me. It's truly transformative.

IM: How did UiPath decide to open a Houston office? What made the city a key market?

MM: Houston — particularly Texas — are both important for us, from a customer perspective. We have some of our larger companies in the country here in Texas, so it was a natural place to look to build capability. Secondly, we're impressed with the overall quality of the market and the availability of different skills here as we build out our company.

IM: What are some goals UiPath has for its new Houston office?

MM: Overall, one of the key goals is to establish a strong Midwest presence for the company. Texas is an ideal location if you think about it for customers that range from the East to the West. Being in the middle is a good, central location. Also, as we grow and expand in Latin America, it's another interesting spot for us. So, one, to ensure that we are able to support the growth needs of the company throughout the United States and leverage the strategic location that Texas has.

I think the other goal is to build some of the core skills we need for the overall organization as we grow in the United States. UiPath is a relatively new player in the U.S., only been here a couple of years.

Finally, we've got terrific customers here, so what's important is to continue to support and nurture those customers. We have a big presence in oil and gas and the support companies within energy.

IM: Tell me about the Academic Alliance and how the company engages with students.

MM: Basically, we offer free training to the universities so that students can get first-hand experience for robotics process automation, which is part of our broader commitment we've made to ensure RBA is available in an open, democratized way.

We are big proponents of supporting students, and we had a great intern program this last summer. We had a double-digit number of interns — I think the largest population in the U.S. We love the fact that we have this access to universities that we can easily tap into.

Just a couple weeks ago we ran UiPath's first-ever hackathon for students in the United States. We had over 50 participants.

We're really excited about building out the ecosystem with the universities and the students here in Houston.

IM: What sort of misconceptions do you encounter within automation?

MM: First and foremost, a lot of it is misconceptions about RPA replacing jobs. I'd say it's a shift in the workforce — I witness this first hand because I had a team where we implemented and built bots. What happens is you create capacity and end up creating new jobs. You have roles of managing bots, bot controllers, bot librarians — these are roles that fundamentally didn't exist five years ago.

IM: What advice do you have for women in tech?

MM: I think it's so critical for women to be in the driving seat and in the forefront of technology. I have two daughters and I'm adamant about how they are exposed to robotics. I did a coffee talk in Houston not too long ago, and I really challenged the women to get out there and get digitally literate. It's really important as women that we don't let ourselves fall behind on technology and how they are impacting both our work and our families. So, staying informed, no matter how you do that — reading, podcasts, news. Another way is to join and network with associations. Myself and another woman important in this space are looking to create a network for women in automation. We want to build a group that will allow women to look for jobs, board roles, mentors, etc. in this industry.

IM: What role do you see Houston playing in the greater innovation conversation and where does the city have room to improve?

​MM: I'm a big fan of Houston. I'm Australian, but I feel like a Texas implant now. It's an incredibly diverse city, and I think that's one of its greatest strengths. You've got people from all walks of life from all parts of the world and a great education system. That creates a really unique backdrop for the technology-led era we're in. The historical strengths of the city have been predicated on the healthy oil and gas sector and medical sector — both are important industries going through major technology transformations. I think for Houston being able to capitalize on all that is a very unique opportunity. It will position Houston very well for the future. You've got the right ingredients here.

Where the city is going to have to continue to build is specifically around some of these skills for the future. Artificial intelligence and having that depth of experience is an area the city struggles in. Certainly other cities like Seattle and San Francisco have tens of years of experience from companies like Google, Facebook, and Amazon that have been able to build deep AI. In Houston, that skillset is going to come more from oil and gas, where they've been building some of those skills, just not in the same breath and not in the same depth as those other cities. I think the real opportunity is to nourish and nurture this in the academic institutions and then take that talent out of the academic institutions and integrate them into the corporations.

------

Portions of this interview have been edited.

UiPath's Houston office is in a historic downtown Houston building that's been renovated. Courtesy of Main&Co

Global automation company doubles down on Houston as it grows its United States presence

New bot on the block

When UiPath decided to look into an office in Houston, it was a bit of a gamble, since Houston's not particularly known for its wealth of hardware talent.

"We did a little bit of an experiment to see what the skills would be like specifically in a Houston office," Marie Myers, CFO of the company and based in Houston, tells InnovationMap. "As a robotics company, we weren't sure if we'd get more of those software skills. It's not a natural market for those skills."

But Houston — and Texas in general — is a great location for the robotics process automation company, Myers says. It's central and optimal for customer acquisition. Valued at $7 billion, UiPath has over 2,500 customers — adding six more a day on average, according to a news release.

Since beginning Houston operations in January, Myers says she's very pleased with the 71-person team the company has assembled locally, and the company has even expanded in that short time. Following a $568 million Series D round closing, the company almost doubled its office size.

"The Series D is critical for us as we continue to grow and we're using those proceeds to grow our base across the world, and obviously part of the Houston expansion has been just that," Myers says.

UiPath plans to really settle into Houston and even bring a an RPA Immersion Lab into its Houston office. The lab would allow for potential customers to try out the technology and run simulations. The lab is on the docket for 2020, Myers says.

Another way UiPath is engaging with the Houston community is through its connection to students and universities. The company has an arrangement with six universities in Houston and is even located just across the street from the University of Houston-Downtown. Myers says the company had one of its largest group of interns working in Houston.

"It's going to be so important for students graduating to have experience in up-and-coming technologies, like RPA," Meyers says. "We see such great support from the local universities."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings